FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Highlighting the safety concerns and educational needs surrounding the use of GLP-1 receptor agonists in clinical practice.
返回研究图书馆
GLP-1 receptor agonistsglucagon-like peptide-1

Highlighting the safety concerns and educational needs surrounding the use of GLP-1 receptor agonists in clinical practice.

May 16, 2026
Share

原始论文

Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.

Mattingly T Joseph et al.Health affairs scholar2026
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文将上述源论文的研究成果分解成肽类研究社区易于理解的语言。我们的目标是突出最值得关注的内容 — 实用意义、证据强度以及对正在进行的研究的影响。

GLP-1 Receptor Agonists: Safety Concerns and Patient Education Needs Highlighted

Published: May 16, 2026 | Source: Health affairs scholar (2026) | Category: GLP-1 receptor agonists, glucagon-like peptide-1

Overview

A new study published in Health Affairs Scholar has revealed that the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with a higher incidence of administration-related adverse events compared to insulin. This finding underscores the importance of patient and provider education, especially as supply shortages have affected availability.

Study Background

GLP-1 receptor agonists are increasingly used in clinical practice for their benefits in managing type 2 diabetes and obesity. However, concerns about safety issues have grown alongside their rapid adoption. Researchers sought to understand the nature and extent of adverse events reported through the FDA's Adverse Event Reporting System (FAERS) between January 2015 and December 2024.

What the Research Found

The study analyzed over 112,000 reports in FAERS data, focusing on GLP-1 receptor agonists and injectable insulin products. Key findings include:

  • Higher Incidence of Administration-Related Events: Among reported adverse events, GLP-1s were associated with a higher share (63%) of administration-related reactions compared to insulin (39%).
  • Increased Reports Post-Supply Shortages: The number of reports involving dosing issues and administration errors for GLP-1 receptor agonists increased significantly starting in Q4 2022, coinciding with national supply shortages.
  • Potential Impact of Increased Utilization: While the study suggests that some increase in reporting volume may reflect higher utilization rather than increased risk due to lack of exposure denominators, it highlights the need for ongoing surveillance.

What This Means for Peptide Users

The findings indicate a critical need for enhanced patient education and provider training on proper administration techniques. Patients using GLP-1 receptor agonists should be vigilant about dosing accuracy and seek guidance from healthcare providers if they encounter difficulties or adverse reactions. Providers are encouraged to closely monitor patients, especially during periods of supply shortages.

Limitations and Caveats

The study relies heavily on voluntary reporting data, which may not capture all adverse events accurately. Additionally, the lack of exposure denominators complicates risk assessment. The analysis also does not account for changes in prescribing patterns or patient behavior over time, which could influence reported outcomes.

How This Compares to Previous Research

Previous studies have highlighted potential side effects and safety concerns associated with GLP-1 receptor agonists but did not focus specifically on administration-related issues. This study provides a more detailed analysis of adverse events during the period of supply shortages, offering new insights into patient education needs and regulatory considerations.

Our Analysis

PeptideVault's assessment suggests that while this study highlights important safety concerns related to GLP-1 receptor agonists, it also underscores the need for ongoing research and surveillance. The findings are valuable in guiding clinical practice but should be interpreted with caution due to limitations inherent in voluntary reporting systems.

Key Takeaways

  • Enhanced Patient Education: Providers must ensure that patients understand proper administration techniques.
  • Regulatory Attention Needed: Continued regulatory oversight is essential, especially during periods of supply shortages.
  • Ongoing Surveillance: Post-marketing surveillance remains crucial for monitoring safety signals and adjusting clinical guidelines as necessary.

Original Source

Citation: Mattingly T Joseph, Duru Emeka Elvis, Conti Rena M (2026). Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.. Health affairs scholar. DOI: 10.1093/haschl/qxag023

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队准备。鼓励读者查阅 完整源论文 以获取完整方法和数据。 原始出版物可在 PubMed.

相关研究

Comments

Sign in to join the discussion

此分析基于同行评审研究仅用于教育目的。并不构成医疗建议。在使用任何肽类疗法之前,请咨询合格的医疗服务提供者。